NMN (β-nicotinamide mononucleotide)

β-Nicotinamide Mononucleotide (NMN)

1. Identity and Chemical Characterisation

1.1 Nomenclature and Structural Identity

Nicotinamide mononucleotide (NMN), formally named Nicotinamide-1-ium-1-β-D-ribofuranoside 5′-phosphate, is a type of bioactive nucleotide naturally formed by the reaction between a phosphate group and a nucleoside containing ribose and nicotinamide. Nicotinamide — the base component of NMN — is one of the two primary forms of vitamin B3 (alongside nicotinic acid), making NMN a vitamin B3 derivative. NMN consists of nicotinamide bonded to a ribose sugar (making it a nucleoside called nicotinamide riboside), with a phosphate group attached to the ribose at the 5′ position (making the complete structure a mononucleotide — one nucleotide). Its molecular formula is C₁₁H₁₅N₂O₈P and its molecular weight is 334.22 g/mol.

NMN exists in α and β anomeric forms, but only the β form possesses biological activity. For this reason, all commercially marketed and experimentally studied preparations are specified as β-NMN. NMN is a pyridine nucleotide which contains a nicotinamide riboside (NR) molecule bounded to a phosphate group. By comparison, NAD+ has a molecular weight of 663.43 g/mol — almost exactly twice that of NMN, reflecting the fact that NAD+ is two nucleotides joined together, with NMN as one of them.

1.2 Relationship to NAD+

NMN is a bioactive nucleotide formed by the reaction between a nucleoside containing ribose, nicotinamide, and a phosphate group. It is a precursor of nicotinamide adenine dinucleotide (NAD+), a crucial cofactor for enzymes involved in major biological processes such as cellular redox regulation and metabolism, and DNA repair. The single-step relationship between NMN and NAD+ is one of the most direct precursor-to-product relationships in cellular biochemistry.

1.3 Natural Sources and Occurrence in Foods

In the human body, NMN is mainly located in the nucleus, mitochondria, and cytoplasm, and can be found in placenta tissue and body fluids such as blood and urine. In vivo, NMN is mainly located in red blood cells, and the amounts required to maintain normal physiological functions can be obtained from the daily diet.

NMN is naturally found in a variety of fruits and vegetables including immature soybean pods, cabbage, cucumber, broccoli, tomato, mushroom, and avocado, as well as in raw beef and shrimp. The NMN content in these vegetables and fruits is 0.25–1.88 mg/100 g and 0.26–1.60 mg/100 g respectively, whereas raw beef and shrimp contain comparatively lower levels of NMN (0.06–0.42 mg/100 g). In dairy products, human milk has been detected to contain NMN as well.

Beetroot has emerged as among the richest sources of NMN among roots and tubers. Among vegetables, bell peppers and tomatoes have been found to contain NMN, NR, and NAD+, with cucumber peel having particularly high NMN content. These natural food sources provide approximately 1 mg of NMN per 100 g of food, making them impractical as a means to acquire the quantities used in clinical dosing regimens.

1.4 Common Supplement Forms and Preparations

NMN is commercially available in several forms. NMN supplements are available on the market and are being ingested by consumers worldwide as healthcare products. Commercially available NMN content generally ranges from 50 to 150 mg per capsule. The primary preparations include oral capsules (standard-release and delayed-release enteric-coated), loose powder for dissolution in liquid, sublingual (dissolve-under-the-tongue) formulations, and liposomal encapsulated formulations. All major clinical trials have used standard NMN, and the clinical studies demonstrating NMN's benefits for insulin sensitivity, physical performance, and biological aging markers all used standard powder or capsule formulations. No peer-reviewed human trial has directly compared sublingual to standard oral NMN on blood NAD+ outcomes.

2. Traditional and Historical Use

NMN as an isolated, characterised compound has no documented history of use in traditional medicine systems. Unlike botanical ingredients such as ashwagandha or ginseng, NMN was not identified as a distinct entity prior to the modern biochemical era; it exists in foods as a trace constituent, not as a recognised therapeutic substance. The broader vitamin B3 family — of which NMN is a derivative — does carry a substantial historical and therapeutic record: niacin (nicotinic acid) was characterised as an essential nutrient in the early twentieth century in the context of pellagra prevention, and nicotinamide has been used clinically as a dietary supplement form of vitamin B3 for decades. However, NMN specifically — as a supplement or therapeutic preparation — is an entirely modern construct. In 2016, researchers first found that NMN effectively alleviated age-related physiological decline in mice without any apparent toxicity, highlighting the potential of NMN supplementation as an anti-aging intervention in humans. The compound attracted widespread supplemental use only after this and related animal studies were published in the mid-2010s, placing NMN firmly in the category of modern nutraceuticals derived from basic science rather than from traditional ethnobotanical or ethnopharmacological practice.

3. Key Constituents, Biochemistry, and Mechanisms of Action

3.1 The NAD+ Salvage Pathway

NAD+ is created in cells by de novo synthesis beginning with tryptophan, the traditional Preiss-Handler method, or the NAD+ salvage pathway, which recycles nicotinamide produced as a byproduct of NAD+-consuming enzymes. The precursors are transformed into NMN in the salvage pathway by the enzyme nicotinamide phosphoribosyltransferase (NAMPT). Then, nicotinamide mononucleotide adenylyltransferase (NMNAT) converts NMN to NAD+.

NAMPT is the rate-limiting enzyme in the mammalian NAD+ salvage pathway and plays a vital role in the regulation of cell metabolic activity, reprogramming, aging, and apoptosis. The NAMPT enzyme in the salvage pathway is considered the cycle's limiting step, and the salvage pathway is estimated to generate approximately 85% of the body's total NAD+.

There are three subtypes of NMNAT: NMNAT-1, which is found in the nucleus; NMNAT-2 exists in the cytoplasm and Golgi apparatus; and NMNAT-3 is expressed in the mitochondria and cytoplasm. This compartmentalised distribution means that NMN-to-NAD+ conversion can occur in multiple subcellular locations, supporting tissue-wide NAD+ homeostasis.

3.2 NAD+ as the Functional Effector

NAD+ is a vital molecule that takes part as a redox cofactor in several metabolic reactions besides being used as a substrate in important cellular signalling in regulation pathways for energetic, genotoxic, and infectious stress. As a signalling molecule, NAD+ serves as a substrate for mono- and poly-ADP-ribosylation of proteins, is required for NAD+-dependent protein deacetylation, and is a precursor for calcium mobilising agents.

NAD+ is utilised by numerous enzymes, including sirtuins, PARPs (poly-ADP-ribose polymerases), and cADPR synthases, to form nicotinamide (NAM), which is then reused in the salvage pathway. In this cycle, NAD+ passes through three depletion pathways (sirtuins, PARPs, and cyclic ADP-ribose synthases) to nicotinamide, which is then converted by NAMPT back to NMN, which is also catalysed by NMNAT1–3 enzymes to NAD+.

Sirtuins (SIRTs) are a family of NAD+-dependent histone deacetylases capable of sensing cellular NAD+ levels. The NAMPT–NAD+–SIRT axis constitutes a powerful anti-stress defence system. The mammalian sirtuin family comprises seven proteins (SIRT1–SIRT7), which act as pivotal regulators of the maintenance of energy homeostasis and prevention of aging-related diseases.

3.3 Age-Related Decline in NAD+

Blood NAD+ concentration declines with chronological age in animals and humans, due to the declined de novo synthesis of NAD+ and the hyperactivity of NAD+-consuming enzymes. Evidence suggests that NAD+ levels may be reduced in humans by up to 80% with increasing age and in numerous diseases, which has stimulated interest in the therapeutic effects of NAD+ boosting. The NAD+ concentration in human skin, blood, liver, muscle, and brain is thought to decrease with age, and finding ways to increase NAD+ status could possibly influence the aging process and associated metabolic sequelae.

3.4 Intestinal Absorption and Pharmacokinetics

When NMN is taken orally, the body uses a specialised transport protein called Slc12a8. This sodium-dependent transporter is located in the small intestine, particularly concentrated in the jejunum and ileum. A specific NMN transporter called Slc12a8 was identified in mouse studies published in 2019, with knockout experiments suggesting this transporter accounts for approximately 80% of intestinal NMN absorption in mice. However, the expression and relative contribution of Slc12a8 in humans remains an area of scientific debate. Studies from 2020–2024 confirmed low but functional levels of this transporter in human gut biopsies, though questions persist about whether dedicated intestinal transporters or alternative mechanisms dominate human NMN absorption. Some researchers suggest that NMN may also be converted to other metabolites in the gut before absorption, with these compounds still contributing to NAD+ pools through different pathways.

NMN is widely investigated as a metabolic precursor to NAD+, where it is assumed that delivery of this compound results in its direct incorporation into NAD+ via the canonical salvage/recycling pathway. Surprisingly, treatment with this salvage pathway intermediate leads to increases in nicotinic acid mononucleotide (NaMN) and nicotinic acid adenine dinucleotide, two members of the Preiss–Handler/de novo pathways. Research has shown that the cell surface enzyme CD38 can mediate a base-exchange reaction on NMN, whereby the nicotinamide ring is exchanged with a free nicotinic acid to yield the Preiss–Handler/de novo pathway intermediate NaMN. This complexity means that oral NMN supplementation may exert its effects through multiple biochemical routes, not exclusively through direct NMN-to-NAD+ conversion.

4. Scientific Evidence by Area of Use

4.1 NAD+ Augmentation: Direct Evidence

The most consistently demonstrated and replicated finding in human NMN trials is the ability of oral supplementation to raise blood NAD+ levels.

A randomised, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial included 80 middle-aged healthy adults randomised for a 60-day clinical trial with once-daily oral dosing of placebo, 300 mg, 600 mg, or 900 mg NMN. The primary objective was to evaluate blood NAD+ concentration with dose-dependent regimens. Blood NAD+ concentrations increased in the 300 mg (approximately threefold), 600 mg (approximately sixfold), and 900 mg groups relative to placebo.

Igarashi et al. found that supplementation with NMN (250 mg/d) in 42 healthy older men (age 65+ years) increased NAD+ levels by sixfold in whole blood (measured by mass spectrometry). NR (~1.4-fold increase), NMN (~1.7-fold increase), nicotinic acid mononucleotide (~23-fold increase), and nicotinic acid riboside (~sevenfold increase) were also increased compared to placebo.

Okabe et al. found that 12 weeks of NMN treatment (250 mg/d) in 29 healthy men and women (age 20–65 years) were safe and increased NAD+ levels in whole blood by approximately 75% (assessed via mass spectrometry). However, no changes to blood panels, blood pressure, or body composition were observed.

A Swiss research team that analysed 65 adults with an average age of 34.7 years administered NR to 16 participants, NMN to 15, nicotinamide (Nam) to 17, and a placebo to 17. The doses were 1 gram of NR, 1 gram of NMN, 0.5 grams of Nam, or placebo daily for 14 days. After 14 days of supplementation, NR and NMN significantly increased circulating NAD+ by approximately two-fold, while Nam had no significant effect. These findings suggest that NR and NMN have similar effects in sustainably raising circulating NAD+ levels.

Evidence strength: The finding that oral NMN raises blood NAD+ levels in humans is consistent and replicated across multiple randomised controlled trials. This is the most robustly established finding in the human NMN literature.

4.2 Metabolic Health: Insulin Sensitivity and Glucose Metabolism

A 10-week, randomised, placebo-controlled, double-blind trial evaluated the effect of NMN supplementation on metabolic function in postmenopausal women with prediabetes who were overweight or obese. Insulin-stimulated glucose disposal (assessed by hyperinsulinemic-euglycemic clamp) and skeletal muscle insulin signalling (phosphorylation of AKT and mTOR) increased after NMN supplementation but did not change after placebo treatment. NMN supplementation up-regulated the expression of platelet-derived growth factor receptor β and other genes related to muscle remodelling. These results demonstrate that NMN increases muscle insulin sensitivity, insulin signalling, and remodelling in women with prediabetes who are overweight or obese. This improvement in muscle insulin sensitivity was reported to be clinically relevant and similar to the improvement observed after approximately 10% weight loss and after 12 weeks of treatment with the insulin-sensitising agent troglitazone in people with obesity.

However, findings in other populations are inconsistent. A study observed physiological muscle motility and blood NAD+ concentrations in 20 healthy older men (age ≥65 years), administering NMN (250 mg) or placebo once daily for 6 or 12 weeks. The NMN intervention did not have an impact on insulin sensitivity, skeletal muscle mass, or visceral fat mass. In the Yi et al. dose-escalation trial, insulin sensitivity was also not affected by supplementation with NMN.

A meta-analysis of eight NMN-centred clinical trials conducted between 2021 and 2023 (dose range 250–2,000 mg/day for a duration of 14 days to 12 weeks), involving a total of 342 mainly non-diabetic and relatively healthy middle-aged and older adults, reported no significant benefit of NMN on lipid profile or glucose control. By contrast, oral supplementation of β-NMN (also known as MIB-626) in older adults with obesity increased circulating NAD+ levels, improved lipid parameters, and reduced diastolic blood pressure.

Evidence strength: Preliminary to moderate. One well-designed human RCT (published in Science) demonstrated improved muscle insulin sensitivity in prediabetic women. However, multiple subsequent trials in different populations — including healthy older adults and healthy middle-aged individuals — showed no effect on insulin sensitivity or metabolic markers. Evidence is population-specific and cannot yet be generalised.

4.3 Physical Function and Exercise Performance

A study investigated the efficacy of oral administration of low-dose (150 mg twice daily), medium-dose (300 mg twice daily), and high-dose (600 mg twice daily) NMN on aerobic exercise capacity in healthy male and female amateur runners for 6 weeks. This study reported a dose-dependent increase in skeletal muscle oxygen utilisation and improvement in aerobic capacity during exercise training.

Several trials reported improvements in selected submaximal or functional measures (such as ventilatory threshold, sit-to-stand time, walk time, and 6-minute walk distance), while other outcomes, particularly VO₂max/peak and grip strength, were frequently unchanged. In the Yi et al. (2023) trial, 6-minute walk distance was significantly greater in all NMN groups than placebo at 30 and 60 days (p < 0.01); in the 600 mg group, distance increased from 290 m at baseline to 435 m at day 60.

In the Igarashi et al. study, select improvements in motor function, such as increased gait speed and grip strength, were observed, but skeletal muscle mass did not change. Additional outcomes such as fat mass, lipids, insulin sensitivity, glucose tolerance, cognitive function, blood pressure, and endothelial function were unchanged after the intervention.

The effects of NMN supplementation combined with exercise training have been reported in healthy amateur runners aged 27–50 years; NMN dose-dependently increased the ventilatory threshold and improved aerobic capacity during exercise training.

Evidence strength: Preliminary. Some RCTs show improvements in submaximal functional measures (walk distance, ventilatory threshold), but the overall picture is inconsistent. Effects on maximal aerobic capacity (VO₂max) and grip strength are not clearly demonstrated. Many positive findings are endpoint-specific and limited by small sample sizes and short durations.

4.4 Cardiovascular and Vascular Health

Preliminary clinical studies in healthy older adults indicate that supplementation with NAD+ precursors such as NMN can reduce arterial stiffness as measured by pulse wave velocity (PWV). However, whether NAD+ supplementation can improve vascular endothelial function and exert anti-stiffening effects in patients who have already developed measurable arterial stiffness remains unknown.

Several trials reported improvements in selected submaximal or functional measures while other outcomes, including VO₂max/peak, were frequently unchanged. Across outcome domains, evidence for clinically meaningful benefit remains inconsistent, with many trials reporting no clear between-group differences for commonly assessed metabolic, vascular, and physical performance endpoints, and positive findings, when observed, were often endpoint-specific or demonstrated in particular populations.

Animal studies have provided more mechanistic detail. In murine experiments, NMN administered by intraperitoneal injection significantly increased the level of NAD+ in the heart at baseline and prevented a decrease in NAD+ during ischemia. Age-associated NAD+ decline has been linked with misregulation of vascular micro-RNA expression, and NMN intraperitoneal treatments resulted in anti-aging transformations in mouse aorta micro-RNA expression profiles.

Evidence strength: Weak to preliminary in humans. Animal evidence is supportive of a biological mechanism, but human RCT data for vascular endpoints are inconsistent and limited in size and duration.

4.5 Neuroprotection and Cognitive Function

In vitro and in vivo studies have demonstrated that NMN supplementation increases NAD+ concentration and could mitigate aging-related disorders such as oxidative stress, DNA damage, neurodegeneration, and inflammatory responses. Ensuring adequate levels of NAD+ is considered indispensable for neuronal survival, whereas its depletion can precipitate a spectrum of neurodegenerative disorders including Alzheimer's disease and Parkinson's disease.

Supplementation of NMN has been demonstrated to stimulate neuroprotective effects and ameliorate cognitive decline and behavioural dysfunctions in animal studies. In vivo intraperitoneal injection of NMN and NMN together with melatonin stimulated neuroprotective effects and alleviated age-associated memory and learning impairments in rats. Administration separately or in combination enhanced mitochondrial function and decreased apoptosis in both hippocampus and prefrontal cortex regions of aged rats.

In human trials, cognitive outcomes have generally not improved. Kim et al. investigated the circadian implications of NMN treatment (250 mg/d) through a comparison of 12 weeks of morning versus afternoon supplementation with NMN or placebo in 108 healthy older men and women (age 65+). They found that sleep quality, fatigue, and physical performance were not different from placebo. Fatigue and sleep outcomes were assessed in a small number of studies with variable measures; some reported improvements in self-reported sleep-quality domains, whereas other studies reported no meaningful change in sleep metrics.

Evidence strength: Preclinical evidence (animal models) is moderately consistent for neuroprotective effects. Human clinical evidence for cognitive or neurological benefit is currently absent or insufficient. No human RCT has demonstrated a statistically significant improvement in validated cognitive endpoints attributable to NMN.

4.6 Aging Biology: General Anti-Aging and Longevity

In preclinical aging and disease models, encouraging improvements in physiological function and healthspan as a result of NAD+ boosting have been observed. A number of rodent studies have shown that NMN improves brain, respiratory system, liver, heart, immune, and reproductive function, yet whether these benefits translate to humans remains to be determined. More human trials are needed to find whether NMN confers the same benefits in humans as it does in rodents.

In the Yi et al. 2023 trial, blood-based analysis of biological age (Aging.AI 3.0 calculator) was unchanged in the NMN-treated groups but increased significantly in the placebo group after 60 days. This finding is exploratory and requires cautious interpretation, as biological age calculators are not validated endpoints in regulatory clinical trials.

Other small-scale clinical trials in humans have shown improved insulin sensitivity, muscle performance, or markers of vascular health, but results are preliminary and call for larger, longer-term research. A recent review found that although NMN appears safe and promising, evidence for significant anti-ageing effects in humans remains limited pending larger-scale studies.

There are early signs of better physical and metabolic health in humans, but no human trials have proven that NMN extends lifespan. That is a claim that would take decades and massive studies to make. The most compelling longevity data on NMN still come from animal studies.

Evidence strength: Animal evidence for longevity and healthspan improvement is robust. Human evidence for anti-aging effects is currently preliminary, inconsistent, and limited by small sample sizes, short study durations, and heterogeneous outcome measures.

4.7 Biological Age, DNA Repair, and Genomic Stability

Preventing the depletion of NAD+ concentration in in vitro studies has demonstrated neuroprotective and cardioprotective effects and has promoted DNA repair. NMN supplementation has been shown in animal studies to prevent DNA damage and accumulation of reactive oxygen species (ROS). These mechanisms are biochemically plausible because PARP enzymes — which are among the primary consumers of NAD+ — are central to DNA strand-break repair; when NAD+ is depleted, PARP activity is compromised and DNA damage may accumulate. However, direct human evidence linking NMN supplementation to improved DNA repair or reduced genomic instability at the clinical level has not been published.

5. Body Systems and Health Areas Associated with NMN

• Metabolic system: Insulin sensitivity, skeletal muscle glucose uptake, and metabolic signalling (AKT/mTOR pathways). Human clinical evidence exists but is limited to specific populations (prediabetic postmenopausal women).
• Musculoskeletal system: Muscle function, gait speed, and aerobic exercise capacity. Some human trial data show improvements in submaximal functional measures; effects on muscle mass and maximal aerobic capacity are not consistently demonstrated.
• Cardiovascular system: Vascular stiffness, endothelial function, lipid parameters, and diastolic blood pressure. Preliminary human and animal evidence; results are inconsistent across trials.
• Nervous system: Neuroprotection, cognitive function, and potential mitigation of neurodegeneration. Primarily animal evidence; human cognitive benefits have not been demonstrated in published RCTs.
• Energy metabolism: NAD+ takes part as a redox cofactor in several metabolic reactions, and NMN, as its precursor, is linked to mitochondrial energy production and cellular ATP generation.
• Genomic integrity: DNA repair via PARP enzymes, which are NAD+-dependent. Mechanistic evidence from animal and cell studies; no direct human clinical evidence.
• Immune and inflammatory response: Animal and cell studies suggest NMN and NR may protect against diabetes, Alzheimer's disease, endothelial dysfunction, and inflammation.
• Sleep and circadian rhythm: Some human trial data show minimal or no effects on sleep quality when measured by validated instruments.

6. Dosage Forms and Dosages Reported in Human Studies

The following dosages reflect what has been tested in published human clinical trials only. No clinical consensus on optimal dosing exists as of the available literature.

• A first human safety study evaluated single oral doses of 100 mg, 250 mg, and 500 mg of NMN in healthy men. Oral administration of NMN did not produce values exceeding normal physiological fluctuations in hematological and clinical biochemical tests.
• A 10-week, randomised, placebo-controlled, double-blind trial used 250 mg/day oral NMN in postmenopausal women with prediabetes who were overweight or obese.
• A 6-week aerobic exercise trial in healthy amateur runners used oral NMN at 150 mg twice daily (300 mg/day), 300 mg twice daily (600 mg/day), and 600 mg twice daily (1,200 mg/day), and reported a dose-dependent increase in skeletal muscle oxygen utilisation and improvement in aerobic capacity.
• A 60-day multicenter RCT randomised 80 healthy middle-aged adults to once-daily oral doses of placebo, 300 mg, 600 mg, or 900 mg NMN.
• Igarashi et al. used 250 mg/day in 42 healthy older men (age 65+ years) for 12 weeks, finding a sixfold increase in whole blood NAD+ levels.
• Okabe et al. administered 250 mg/day for 12 weeks in 29 healthy adults (age 20–65), finding approximately 75% increase in whole blood NAD+.
• A Japanese safety trial evaluated 1,250 mg of β-NMN administered orally once daily for up to 4 weeks in 31 healthy adult men and women aged 20–65 years.
• A 2025 Nature Metabolism study used 1 gram NMN per day for 14 days in healthy adults.

NMN is being evaluated in registered trials for effects on cardiometabolic function, for efficacy in hypertensive patients, and as an anti-aging supplement at doses ranging from 200 to 500 mg/day for durations of 29 days to 16 weeks.

7. Safety Considerations

7.1 General Safety Profile from Clinical Trials

Supplementation with NMN appears to be safe for up to 24 weeks and, when measured, tends to boost at least some components of the NAD+ metabolome. However, the efficacy of NMN for improving physiological function is less clear.

In the 1,250 mg/day safety trial, oral administration of β-NMN did not result in changes exceeding physiological variations in multiple clinical measures, including anthropometry, hematological, biochemical, urine, and body composition analyses. No severe adverse events were observed during the study period. The results indicated that β-NMN is safe and well-tolerated in healthy adult men and women at an oral dose of 1,250 mg once daily for up to 4 weeks.

In the Igarashi 2022 trial (250 mg/day, 12 weeks, 42 men over 65), no adverse events were reported, and blood panels, blood pressure, and body composition remained unchanged. In the Yi et al. (2023, GeroScience) trial (300/600/900 mg/day, 60 days, 80 adults), no serious adverse events were observed at any dose level. Some participants reported mild, transient GI symptoms that investigators determined were unrelated to NMN. In the Okabe et al. (2022, Endocrine Journal) trial (250 mg/day, 12 weeks, 29 adults aged 20–65), no adverse events were reported, and blood chemistry panels showed no changes indicative of safety concerns.

More than a dozen human clinical trials administering NAD+ precursors at different doses for up to 26 weeks (with one lasting two years) have consistently demonstrated their safety.

7.2 High-Dose Safety

Previous clinical studies with NMN had not reported on the safety of repeated daily oral administration of ≥1,000 mg/shot in healthy adult men and women, and human clinical trials on NMN safety have been limited at high doses. The 1,250 mg/day 4-week Japanese trial and the dose-escalation study up to 1,200 mg/day in Chinese runners are among the highest-dose published data. Liao et al. tested NMN at doses ranging from 100 mg to 1,200 mg per day over multiple weeks. Even at the highest dose of 1,200 mg per day, no serious adverse events were recorded; mild, transient GI discomfort was noted in a small number of participants at the highest dose tier but resolved without intervention.

7.3 Long-Term Safety Data Limitations

The safety of NMN doses over the long term cannot be fully assessed since the required clinical and toxicological studies have not been completed to establish recommended safe levels for long-term administration. Most trials have been limited to durations of 4–12 weeks. No formal NOAEL (no observed adverse effect level) has been established for NMN in humans.

7.4 Theoretical Concerns: Cancer and Cellular Senescence

A concern that has been raised in the scientific literature is a theoretical cancer risk. The reasoning is that NAD+ is required for rapidly dividing cells, so raising NAD+ levels could theoretically fuel tumor growth. This concern is mechanistically plausible but has not been observed in any human NMN trial.

Although no clear side effects have been reported in existing human clinical trials, some studies have reported possible concerns in specific model systems. Di Stefano et al. reported a prodegenerative effect on axons after NMN supplementation in a chemotherapy-induced peripheral neuropathy mouse model and identified the NMN-synthesising enzyme as an important new therapeutic target in axonopathies. Nacarelli et al. found that NMN supplementation could enhance the pro-inflammatory SASP (senescence-associated secretory phenotype) in oncogene-induced senescence cells and promote pancreatic ductal adenocarcinoma progression in a mouse model driven by oncogenic Kras. These preclinical findings have not been replicated in or translated to human clinical studies, but they underscore the importance of caution in populations with cancer or those at elevated cancer risk.

7.5 Regulatory Status

Production of nicotinamide mononucleotide in the United States as a dietary supplement was prohibited in 2022 by the FDA because it was under investigation as a pharmaceutical drug. The FDA has since rescinded this determination for the β-NMN form. NR has been granted Generally Recognised as Safe (GRAS) status by the US FDA, a designation that had not been achieved for NMN as of prior reporting. Multiple human clinical trials have consistently demonstrated the short-term safety of NAD+ precursors including NMN at the doses studied.

7.6 Gut Microbiome Interactions

Emerging research has begun to examine the interplay between NAD+ precursors including NMN and gut microbiota, suggesting a bidirectional relationship between intestinal bacterial metabolism of NMN and systemic NAD+ levels. Research indicates that gut microbiota converts a portion of oral NMN to nicotinamide and nicotinic acid through a process called deamidation. This metabolic conversion may affect the extent to which intact NMN reaches systemic circulation, but the resulting nicotinamide metabolites still contribute to the NAD+ pool via their own biosynthetic pathways.

8. Methodological Limitations of the Existing Evidence Base

Recent animal and preliminary clinical studies suggest moderate efficacy and good safety for NMN, although several translational challenges — including species-specific pharmacokinetics and product heterogeneity — persist. Age-related variations in NAD+ levels across tissues and changes in tissue NAD+ due to boosting strategies are inconsistent, making the current functional relevance of tissue NAD+ levels unclear.

Leading researchers have acknowledged the need for improved tools, biomarkers, and clinical trial designs to better assess the potential benefits of NAD+ boosting supplements, especially in light of the poorly understood complexities of the NAD+ metabolome. Limitations specific to the NMN literature include: short trial durations (most ≤12 weeks); small sample sizes; heterogeneous populations; varied NAD+ measurement methodologies (mass spectrometry vs. colorimetric kits); absence of validated clinical endpoints directly linked to NAD+ biology; and a reliance on animal models whose translatability to humans is not established.

Preclinical studies are more uniformly positive across metabolic, neuromuscular, vascular, and neurobehavioural domains, supporting biological plausibility for NAD+-linked pathways in aging biology. The gap between preclinical promise and human clinical demonstration remains the central challenge in the NMN research field.

References

• Nadeeshani H et al. NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health. PMC, 2023.
• Tan Z et al. Advances in the Synthesis and Physiological Metabolic Regulation of Nicotinamide Mononucleotide. PMC (Nutrients), 2024.
• Unraveling nicotinamide mononucleotide (NMN): A critical review of health implications, synthesis pathways, and analytical techniques. ScienceDirect, 2026.
• Nadeeshani H et al. Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns. PMC (Journal of Advanced Research), 2022.
• Determination of NAD+ precursors NMN and NR in plant foods: exploring dietary sources. Food & Function, 2025.
• Poddar SK et al. Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule. PMC, 2019.
• Zhang Y et al. The function of nicotinamide phosphoribosyl transferase (NAMPT) and its role in diseases. Frontiers in Molecular Biosciences, 2024.
• Yang Y et al. An Updated Review on the Mechanisms, Pre-Clinical and Clinical Comparisons of NMN and NR. Food Frontiers, 2025.
• Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 2021 (PMC).
• Igarashi M et al. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. NPJ Aging, 2022 (PMC).
• Yi L et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 2022 (PMC).
• Huang H. A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement). Frontiers in Aging, 2022 (PMC).
• Okabe K et al. Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. PMC, 2022.
• Freeberg KA et al. Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions. Journal of Gerontology, 2023 (PMC).
• The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. PMC (Advances in Nutrition), 2023.
• NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. ScienceDirect (Ageing Research Reviews), 2026.
• Nicotinamide Mononucleotide Is Safely Metabolized and Significantly Reduces Blood Triglyceride Levels in Healthy Individuals. PMC, 2022.
• Christen M et al. CD38 mediates nicotinamide mononucleotide base exchange to yield nicotinic acid mononucleotide. PMC, 2025.
• Potential Synergistic Supplementation of NAD+ Promoting Compounds as a Strategy for Increasing Healthspan. PMC (Nutrients), 2023.
• Clinical evidence for the use of NAD+ precursors to slow aging. GeroMedicine, 2025.
• Yamamoto T et al. Nicotinamide Mononucleotide, an Intermediate of NAD+ Synthesis, Protects the Heart from Ischemia and Reperfusion. PMC, 2014.
• Shade C. The Science Behind NMN – A Stable, Reliable NAD+ Activator and Anti-Aging Molecule. Integrative Medicine (Encinitas), 2020 (PMC).
• Tan Z et al. Biosynthesis of β-nicotinamide mononucleotide from glucose via a new pathway in Bacillus subtilis. Frontiers in Microbiology, 2024 (PMC).
• Nicotinamide mononucleotide. Wikipedia (for regulatory status cross-reference only).